Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Acumen Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ABOS
Nasdaq
8731
https://acumenpharm.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Acumen Pharmaceuticals Inc
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q3 2023 Earnings Call Transcript
- Nov 14th, 2023 1:53 pm
Q3 2023 Acumen Pharmaceuticals Inc Earnings Call
- Nov 14th, 2023 4:08 am
Acumen Pharmaceuticals Inc (ABOS) Reports Q3 2023 Financial Results and Provides Business Update
- Nov 13th, 2023 3:54 pm
Thinking about buying stock in Tivic Health Systems, Tigo Energy, TAT Technologies, Plus Therapeutics, or Acumen Pharmaceuticals?
- Nov 13th, 2023 2:31 pm
Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights
- Nov 13th, 2023 12:00 pm
Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures
- Nov 13th, 2023 12:00 pm
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
- Nov 7th, 2023 9:01 pm
Q3 2023 Halozyme Therapeutics Inc Earnings Call
- Nov 7th, 2023 4:22 pm
Acumen Pharmaceuticals to Report Third Quarter Financial Results on November 13, 2023
- Nov 6th, 2023 9:01 pm
Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE® Technology
- Nov 6th, 2023 12:30 pm
Acumen Pharmaceuticals to Participate in the UBS Biopharma Conference
- Nov 2nd, 2023 8:00 pm
Acumen Pharmaceuticals Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen and Safety Findings for ACU193 in Early Alzheimer’s Disease at the 16th Annual Clinical Trials on Alzheimer’s Disease
- Oct 27th, 2023 1:25 pm
Acumen Pharmaceuticals to Present Deeper Insights from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s During Symposium at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD)
- Oct 4th, 2023 12:00 pm
Acumen Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
- Sep 19th, 2023 8:00 pm
Acumen Pharmaceuticals, Inc.'s (NASDAQ:ABOS) largest shareholders are private equity firms with 38% ownership, individual investors own 26%
- Sep 17th, 2023 12:19 pm
Acumen Pharmaceuticals to Participate in the H.C. Wainwright Annual Global Investment Conference
- Sep 6th, 2023 8:00 pm
Q2 2023 Acumen Pharmaceuticals Inc Earnings Call
- Aug 9th, 2023 2:21 am
Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights
- Aug 8th, 2023 11:00 am
Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 8, 2023
- Aug 1st, 2023 8:00 pm
Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans
- Jul 25th, 2023 5:47 pm
Scroll